Placebo effect of medication cost in Parkinson disease: A randomized double-blind study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the effect of cost, a traditionally "inactive" trait of intervention, as contributor to the response to therapeutic interventions. METHODS: We conducted a prospective double-blind study in 12 patients with moderate to severe Parkinson disease and motor fluctuations (mean age 62.4 ± 7.9 years; mean disease duration 11 ± 6 years) who were randomized to a "cheap" or "expensive" subcutaneous "novel injectable dopamine agonist" placebo (normal saline). Patients were crossed over to the alternate arm approximately 4 hours later. Blinded motor assessments in the "practically defined off" state, before and after each intervention, included the Unified Parkinson's Disease Rating Scale motor subscale, the Purdue Pegboard Test, and a tapping task. Measurements of brain activity were performed using a feedback-based visual-motor associative learning functional MRI task. Order effect was examined using stratified analysis. RESULTS: Although both placebos improved motor function, benefit was greater when patients were randomized first to expensive placebo, with a magnitude halfway between that of cheap placebo and levodopa. Brain activation was greater upon first-given cheap but not upon first-given expensive placebo or by levodopa. Regardless of order of administration, only cheap placebo increased activation in the left lateral sensorimotor cortex and other regions. CONCLUSION: Expensive placebo significantly improved motor function and decreased brain activation in a direction and magnitude comparable to, albeit less than, levodopa. Perceptions of cost are capable of altering the placebo response in clinical studies. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that perception of cost is capable of influencing motor function and brain activation in Parkinson disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015591 · Cited by 900 · cited 1×
“Given that the benevolent use of deception to generate a placebo response is in conflict with the principle of respect for patient autonomy, preliminary data suggest that the use of “nonblind placebo” (inert content disclosed) may be effective(36) and eliminate the need for deception or concealment even in a randomize…”
BackgroundWhy Don't We Move Faster? Parkinson's Disease, Movement Vigor, and Implicit Motivation
Mazzoni, P., Hristova, A., & Krakauer, J. W. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0264-07.2007 · Cited by 557
Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans
Tracey, I. (2010) · Nature Medicine · doi:10.1038/nm.2229 · Cited by 553 · cited 1×
“It is well recognized that expectation of a response to treatment is a great modulator of behavior.(4) Thus, probing the neurobiological basis of the placebo response is important to understand the complex response to various medical and surgical interventions and for devising strategies aimed at harnessing its benefi…”
BackgroundDüzel, E., Bunzeck, N., Guitart-Masip, M., & Düzel, S. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.006 · Cited by 249 · cited 1×
“”(21) Dopaminergic upregulation of the same pathways affected by PD is correlated with positive anticipation, motivation, and response to novelty in normal subjects.(22) Saline injection given to subjects with PD believing to have received an active drug and, thus, demonstrating an “expectation of reward” response, is…”
BackgroundRandomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009) · Movement Disorders · doi:10.1002/mds.22401 · Cited by 143
Cited by
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0375-5 · Cited by 276
The paradox of sham therapy and placebo effect in osteopathy: A systematic review
Cerritelli, F., Verzella, M., Cicchitti, L., D’Alessandro, G., & Vanacore, N. (2016) · Medicine · doi:10.1097/md.0000000000004728 · Cited by 65
Placebo and nocebo effects across symptoms: from pain to fatigue, dyspnea, nausea, and itch
Wolters, F., Peerdeman, K. J., & Evers, A. W. M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00470 · Cited by 57
Metadata
- Authors
- Espay, A. J., Norris, M. M., Eliassen, J. C., Dwivedi, A., Smith, M. S., Banks, C., Allendorfer, J. B., Lang, A. E., Fleck, D. E., Linke, M. J., & Szaflarski, J. P.
- Venue
- Neurology
- Published
- 2015-02-24
- Volume
- 84
- Issue
- 8
- Pages
- 794-802
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2171504304
- Cited by
- 145
- References
- 7
- FWCI
- 11.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Placebo effect of medication cost in Parkinson disease: A randomized double-blind study. https://app.cochat.ai/papers/10.1212/wnl.0000000000001282
- The paper
- Espay, A. J., Norris, M. M., Eliassen, J. C., Dwivedi, A., Smith, M. S., Banks, C., Allendorfer, J. B., Lang, A. E., Fleck, D. E., Linke, M. J., & Szaflarski, J. P. (2015). Placebo effect of medication cost in Parkinson disease: A randomized double-blind study. Neurology. https://doi.org/10.1212/wnl.0000000000001282
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.